<DOC>
	<DOCNO>NCT02705274</DOCNO>
	<brief_summary>Protocol S DRCR.net show receive Ranibizumab anti-vascular endothelial growth factor ( anti-VEGF ) therapy defer panretinal photocoagulation ( PRP ) non-inferior eye receive standard prompt PRP therapy , however visual functional benefit le complication Ranibizumab arm . Applying Protocol S real world scenario may add cost burden patient patient need 7 injection per year cost patient 7000 US dollar year minimum The primary objective protocol determine visual acuity outcomes 1 year eye proliferative diabetic retinopathy ( PDR ) use Bevacizumab 1.25 mg instead Ranbizumab low cost burden</brief_summary>
	<brief_title>PRP v Bevacizumab PDR Treatment</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age &gt; = 18 year Diagnosis diabetes mellitus ( type 1 type 2 ) Presence PDR investigator intend manage PRP alone PRP defer least 4 week set intravitreal Bevacizumab , investigator 's judgment . Best correct Snellen equivalent 20/320 high day randomization . Media clarity , pupillary dilation , study participant cooperation sufficient administer PRP obtain adequate fundus photograph OCT . Significant renal disease , define history chronic renal failure require dialysis kidney transplant . Myocardial infarction , acute cardiac event require hospitalization , stroke , transient ischemic attack , treatment acute congestive heart failure within 4 month prior randomization Systemic antiVEGF proVEGF treatment within 4 month prior randomization . For woman childbearing potential : pregnant lactate intend become pregnant within next 3 year . Tractional retinal detachment involve macula . A tractional retinal detachment exclusion outside posterior pole ( threaten macula ) investigator 's judgment , contraindication intravitreal Bevacizumab treatment also preclude defer PRP least 4 week set intravitreal Bevacizumab Macular edema present consider related ocular surgery cataract extraction orclinical exam and/or OCT suggest vitreoretinal interface abnormality disease ( e.g. , taut posterior hyaloid epiretinal membrane ) primary cause macular edema . An ocular condition present ( diabetic retinopathy ) , opinion investigator , might alter visual acuity course study ( e.g. , retinal vein artery occlusion , uveitis ocular inflammatory disease , neovascular glaucoma , Substantial cataract , opinion investigator , likely decrease visual acuity 3 line ( i.e. , cataract would reduce acuity 20/40 bad eye otherwise normal ) . History intravitreal antiVEGF treatment time past 2 month . History corticosteroid treatment ( intravitreal ) time past 4 month . History major ocular surgery ( include vitrectomy , cataract extraction , scleral buckle , intraocular surgery , etc . ) within prior 4 month anticipate within next 6 month follow randomization . Exam evidence severe external ocular infection , include conjunctivitis , chalazion , substantial blepharitis Uncontrolled glaucoma ( investigator 's judgment ) . Aphakia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>